Transaction DateRecipientSharesTypePriceValue
6th January 2021Stefanie L. Cavanaugh218Other acquisition or disposition$0.00
5th January 2021Todd Newton3,479Other acquisition or disposition$0.00
4th January 2021Julie Ann Shimer4,005Grant/award etc.$0.00
23rd December 2020Inc Cpmg103,185Other acquisition or disposition$0.00
23rd December 2020Inc Cpmg63,481Other acquisition or disposition$0.00
23rd December 2020R Kent Jr Mc Gaughy166,666Other acquisition or disposition$0.00
12th November 2020William D. Jr. Mc Clellan488Open or private sale$174.82$85,311.96
12th November 2020William D. Jr. Mc Clellan970Open or private sale$173.21$168,018.36
12th November 2020William D. Jr. Mc Clellan2,542Open or private sale$172.44$438,338.41
12th November 2020William D. Jr. Mc Clellan4,000Conversion of derivative$0.00
Apollo Endosurgery
Apollo Endosurgery logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Apollo Endosurgery, Inc. engages in the design, development, and commercialization of medical devices. It offers medical devices for bariatric and gastrointestinal procedures under the ORBERA and OverStitch brands.

Ticker: APEN
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1251769
Employees: 217
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $19 M (-36%)
Inventory, Net: $11 M (0%)
Assets, Current: $39 M (-23%)
Other Assets, Noncurrent: $3 M (3%)
Assets: $60 M (-19%)
Long-term Debt, Current Maturities: $5 M (0%)
Accounts Payable, Current: $7 M (-27%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $19 M (-63%)
Liabilities: $71 M (-2%)
Common Stock, Value, Issued: $21 Th (0%)
Common Stock, Shares, Issued: $21 M (1%)
Retained Earnings (Accumulated Deficit): $267 M (6%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 M (147%)
Stockholders' Equity (Parent): $11 M (0%)
Liabilities and Equity: $60 M (-19%)
Revenue: $6 M (0%)
Cost of Revenue: $3 M (-61%)
Gross Margin: $2 M (-69%)
Research and Development: $2 M (-54%)
Sales and Marketing: $2 M (-73%)
General and Administrative Expenses: $2 M (-60%)
Operating Income/Loss: $4 M (-60%)
Income before taxes: $6 M (-62%)
Provision for income taxes: $6 Th (-87%)